identifi
potenti
therapeut
stopgap
evalu
librari
approv
refer
compound
unbias
cellular
imagebas
screen
abil
suppress
broad
impact
viru
phenom
profil
human
renal
cortic
epitheli
cell
use
deep
learn
assay
remdesivir
antivir
test
strong
efficaci
neither
chloroquin
hydroxychloroquin
benefici
effect
human
cell
model
small
number
compound
current
pursu
clinic
efficaci
observ
weak
benefici
class
effect
blocker
inhibitor
vitamin
analogu
mild
amplif
viral
phenotyp
agonist
novel
unexpect
signal
could
come
disrupt
interact
viru
host
modul
cytokin
signal
identifi
human
model
suitabl
high
throughput
screen
infect
monolay
normal
human
renal
cortic
epitheli
cell
hrce
well
normal
human
bronchial
epitheli
cell
cell
fix
stain
imag
cell
hour
post
infect
describ
previous
figur
supplement
figur
b
also
infect
african
green
monkey
kidney
epitheli
cell
vero
control
condit
supplement
figur
evalu
specif
phenotyp
profil
impact
viru
compar
effect
activ
inact
ultravioletirradi
uvir
mock
prepar
cell
imag
process
use
proprietari
deep
learn
neural
network
gener
highdimension
featur
imag
identif
distinct
phenotyp
profil
hrce
vero
cell
demonstr
robust
phenotyp
compar
mock
irradi
control
zfactor
hrce
activ
viru
vs
mock
hrce
activ
viru
vs
irradi
vero
activ
viru
vs
mock
vero
activ
viru
vs
irradi
figur
notabl
phenom
assay
achiev
aforement
highli
separ
assay
window
hrce
without
signific
chang
cell
count
time
point
compar
mock
uvir
control
hrce
select
screen
due
diseas
relev
robust
diseasespecif
phenotyp
repres
imag
hrce
infect
control
well
includ
composit
imag
individu
channel
uniqu
stain
b
distribut
histogram
test
split
control
group
xaxi
repres
ondiseas
score
yaxi
number
well
treat
well
pink
control
well
blue
control
type
left
column
mock
right
column
uv
irradi
viru
cell
type
top
row
vero
bottom
row
hrce
chemic
suppressor
screen
conduct
treat
hrce
cell
six
halflog
dose
six
replic
per
dose
compound
approxim
two
hour
cell
seed
hour
post
seed
cell
infect
moi
incub
hour
fixat
stain
imag
follow
imag
compound
evalu
impact
morpholog
profil
infect
defin
differ
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
activ
viru
mock
condit
ondiseas
score
plu
overal
impact
element
cell
morpholog
associ
diseas
model
offdiseas
score
figur
supplement
figur
vero
cell
chloroquin
lopinavir
remdesivir
exhibit
diseas
score
suppress
activ
valu
similar
previous
establish
cytopath
effect
cpe
viral
nprotein
express
assay
proprietari
hit
score
algorithm
base
compar
ondiseas
vs
offdiseas
score
doserespons
use
determin
efficaci
compound
figur
vast
major
compound
current
report
evalu
human
clinic
trial
show
weak
ondiseas
efficaci
figur
next
report
three
compound
current
trial
demonstr
moder
strong
effect
model
two
clinicalstag
asset
ad
librari
base
silico
vitro
analys
suggest
potenti
util
aloxistatin
irrevers
cystein
proteas
inhibitor
initi
develop
muscular
dystrophi
advanc
phase
japan
figur
recent
studi
confirm
cystein
proteas
cathepsin
l
requir
viral
entri
aloxistatin
treatment
reduc
cellular
entri
pseudovirion
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
silmitasertib
select
inhibitor
protein
kinas
casein
kinas
current
clinic
develop
oncolog
figur
recent
suggest
therapeut
target
base
larg
scale
interactom
data
hypothes
promot
antivir
cellular
state
reduc
turnov
stress
granul
altern
result
suggest
inhibit
may
prevent
nucleocapsid
shuttl
nucleu
cytoplasm
almitrin
respiratori
stimul
use
acut
respiratori
failur
chronic
obstruct
pulmonari
diseas
copd
avail
europ
current
avail
us
figur
recent
structurebas
comput
studi
hypothes
almitrin
bind
main
viral
proteinas
mpro
import
viral
target
given
necess
protein
viral
replic
result
demonstr
first
time
activ
almitrin
human
cell
infect
suggest
almitrin
may
repres
novel
proteasetarget
antivir
identifi
chemic
class
compound
across
class
display
weak
consist
rescu
reason
welltoler
human
offer
potenti
element
combin
therapi
significantli
enrich
class
molecul
identifi
betaadrenerg
receptor
antagonist
molecul
demonstr
threshold
activ
supplement
figur
p
among
activ
molecul
class
carvedilol
celiprolol
molecul
combin
beta
alpha
adrenerg
blockad
properti
thought
enhanc
effect
drug
patient
combin
heart
failur
copd
associ
beta
adrenerg
blocker
use
previous
demonstr
given
elev
risk
mortal
among
patient
preexist
heart
diseas
intrigu
consid
whether
subclass
may
offer
enhanc
benefit
patient
second
mechanist
class
demonstr
enrich
sirolimu
deriv
compound
two
three
inhibitor
demonstr
threshold
activ
supplement
figur
p
therapeut
benefit
mtor
modul
agent
hypothes
base
human
proteinprotein
interactom
result
suggest
enrich
interact
viral
protein
human
target
similarli
system
comput
pharmacolog
approach
predict
sirolimu
put
therapeut
base
protein
network
map
notabl
inhibit
mtor
sirolimu
reduc
merscov
infect
cellbas
studi
furthermor
diabet
repres
second
major
risk
factor
sever
given
dysregul
mtor
signal
diabet
state
appeal
consid
result
may
reveal
mechanist
basi
advers
outcom
patient
third
mechanist
class
demonstr
signific
enrich
among
activ
screen
vitamin
receptor
agonist
supplement
figur
p
role
vitamin
immun
well
establish
vitamin
supplement
subject
ongo
investig
studi
limit
evid
support
benefici
role
vitamin
prevent
resolut
infect
larg
metaanalysi
acut
respiratori
tract
infect
found
supplement
benefici
overal
protect
patient
baselin
vitamin
defici
lastli
sever
notabl
mechanist
class
demonstr
lack
activ
significantli
enrich
among
molecul
trend
toward
amplifi
diseas
phenotyp
ace
inhibitor
angiotensin
receptor
blocker
arb
subject
interest
given
widespread
use
report
viral
entri
cell
via
receptor
class
show
signific
activ
howev
betaadrenerg
receptor
agonist
albuterol
formoterol
commonli
administ
bronchodil
led
statist
signific
amplif
phenotyp
supplement
figur
p
may
warrant
caution
patient
togeth
data
show
first
time
highdimension
analysi
approv
drug
human
cellular
model
infect
although
vitro
screen
repres
data
singl
human
cell
type
hrce
method
like
broadli
applic
primari
human
cell
model
data
may
use
basi
priorit
work
given
constrain
resourc
serv
gener
hypothes
research
rapidli
progress
field
case
data
serv
basi
ongo
effort
identifi
cocktail
addit
synergist
oral
avail
rapidli
manufactur
safe
fdaapprov
drug
robust
activ
studi
anim
human
stopgap
vaccin
broadli
utiliz
remdesivir
final
sign
agreement
partner
facil
submit
data
requir
week
optim
type
work
could
potenti
conduct
week
across
much
larger
chemic
librari
suggest
broad
approachwhich
abl
identifi
vitro
signal
efficaci
across
wide
varieti
mechan
could
robust
tool
rapid
therapeut
discoveri
futur
pandem
supplement
method
nearli
immunofluoresc
imag
underli
report
made
publicli
avail
rxrxai
along
deep
learn
embed
imag
titl
dataset
strain
propag
vero
cell
atcc
cell
grown
standard
tissu
cultur
flask
confluenc
infect
multipl
infect
moi
eagl
minimum
essenti
medium
emem
fetal
bovin
serum
fb
gml
gentamicin
incub
day
supernat
contain
viru
remov
cultur
spun
remov
cellular
debri
store
use
viral
titer
determin
standard
tissu
cultur
infecti
dose
method
cytopath
effect
cpe
vero
cell
measur
visual
observ
light
microscop
creat
suitabl
control
inactiv
viru
irradi
uv
lamp
minut
viral
inactiv
sampl
verifi
use
visual
cpe
vero
cell
undetect
level
activ
viru
observ
addit
mock
control
creat
use
condit
media
prepar
gener
uninfect
vero
cell
grown
fb
emem
five
day
cellular
debri
remov
centrifug
supernat
frozen
use
experi
use
perform
utah
state
univers
use
biosafeti
level
contain
procedur
fivechannel
imag
embed
featur
space
use
proprietari
deep
convolut
neural
network
train
imag
cellular
imag
dataset
recurs
previous
made
public
rxrxai
postprocess
extract
featur
includ
normal
remov
interpl
varianc
pca
reduc
featur
space
anomali
detect
remov
outlier
activ
uv
inactiv
mock
condit
featur
effici
repres
infect
verifi
logist
regress
classifi
vector
point
barycent
mock
activ
viru
treat
condit
comput
extract
featur
decompos
sign
scalar
project
ondiseas
score
scalar
reject
offdiseas
score
respect
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
vector
score
normal
mean
diseas
score
mock
condit
activ
viru
condit
supplement
tabl
separ
mock
activ
viru
condit
along
diseas
axi
verifi
zfactor
compound
dose
assign
hit
score
use
proprietari
algorithm
priorit
low
ondiseas
score
penal
high
offdiseas
score
highest
possibl
hit
score
compound
two
bestscor
dose
use
comput
overal
hit
score
supplement
tabl
hit
select
individu
compound
hit
score
compound
class
consist
show
hit
score
hypergeometr
test
pvalu
less
code
underli
report
leverag
proprietari
algorithm
imag
process
data
standard
outlier
detect
compound
efficaci
score
code
underli
report
made
avail
instead
much
output
algorithm
provid
supplement
tabl
ccbync
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
